Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ilaprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 8/20 | 0.40 |
| ▸ | ATP4B known ✓ | P51164 | 8/20 | 0.40 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.40 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.40 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.40 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.40 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.40 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.40 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.40 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilaprazole SCHEMBL29684589 | 0.99 | ATP4A (0.39) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL28829587 | 0.98 | ATP4A (0.39) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL1179039 | 0.93 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL22734706 | 0.93 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL29364741 | 0.93 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL23988478 | 0.93 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL22734704 | 0.93 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL8470106 | 0.92 | ATP1A1 (0.36) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL14022064 | 0.86 | ATP1A1 (0.32) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| Ilaprazole SCHEMBL14022063 | 0.86 | ATP1A1 (0.33) | ATP4AATP4BATP1A1ATP1B1ATP1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118252810-B | Preparation method of ilaprazole enteric-coated tablets | 寿光富康制药有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-118252810-A | Preparation method of ilaprazole enteric-coated tablets | 寿光富康制药有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11666562-B2 | Ilaprazole for inhibiting the release of enveloped viruses from cells | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666562-B2 | Ilaprazole for inhibiting the release of enveloped viruses from cells | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666562-B2 | Ilaprazole for inhibiting the release of enveloped viruses from cells | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210308114-A1 | ILAPRAZOLE FOR INHIBITING THE RELEASE OF ENVELOPED VIRUSES FROM CELLS | NORTHWESTERN UNIVERSITY | 2021-10-07 | — | — | US | disclosed |
| US-20210308114-A1 | ILAPRAZOLE FOR INHIBITING THE RELEASE OF ENVELOPED VIRUSES FROM CELLS | NORTHWESTERN UNIVERSITY | 2021-10-07 | — | — | US | disclosed |
| CN-112168965-A | Use of SRCAP ATPase agonists in the treatment of disorders mediated by the inhibition of intestinal stem cell self-renewal | 中国科学院生物物理研究所 | 2021-01-05 | — | — | CN | disclosed |
| CN-107468689-A | A kind of TOPK inhibitor with antitumor action | 武汉华杰世纪生物医药有限公司 | 2017-12-15 | — | — | CN | disclosed |
| WO-2013114232-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE FORM L OF ILAPRAZOLE | LUPIN LIMITED (IN) | 2013-08-08 | — | — | WO | disclosed |
| EP-1861391-B1 | METHODS FOR PREPARING SUBSTITUTED SULFOXIDE COMPOUNDS | LIVZON PHARMACEUTICAL GROUP (CN) | 2011-10-12 | — | — | EP | disclosed |
| US-8017784-B2 | Antisecretory agents; antiulcer agents | LIVZON PHARMACEUTICAL GROUP, INC. (CN) | 2011-09-13 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1861391-A4 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | LIVZON PHARMACEUTICAL GROUP IN (CN) | 2008-11-05 | — | — | EP | disclosed |
| US-20080234487-A1 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | LIVZON PHARMACEUTICAL GROUP, INC. (CN) | 2008-09-25 | — | — | US | disclosed |
| EP-1861391-A1 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | Livzon Pharmaceutical Group Inc. (CN) | 2007-12-05 | — | — | EP | disclosed |
| US-20060217423-A1 | Substituted sulfoxide compounds, methods for preparing the same and use thereof | LIVZON PHARMACEUTICAL GROUP, INC. (CN) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099810-A1 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | LIVZON PHARMACEUTICAL GROUP INC. (CN) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234487-A1 | SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF | STS, SRM, MPST | ATP4A 4395/4885ATP4B 3981/4885ATP1A1 2019/4885 |
| US-20210308114-A1 | ILAPRAZOLE FOR INHIBITING THE RELEASE OF ENVELOPED VIRUSES FROM CELLS | TMPRSS15, PREP, HAVCR2 | ATP4A 966/4885ATP4B 627/4885ATP1A1 1766/4885 |
| US-11666562-B2 | Ilaprazole for inhibiting the release of enveloped viruses from cells | TMPRSS15, PREP, HAVCR2 | ATP4A 966/4885ATP4B 627/4885ATP1A1 1766/4885 |
| US-20060217423-A1 | Substituted sulfoxide compounds, methods for preparing the same and use thereof | STS, SRM, MPST | ATP4A 4395/4885ATP4B 3981/4885ATP1A1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.